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ABSTRACT
This study is aimed to find out the effectiveness of oral 600 mcg single dose misoprostol
for the evacuation of conception remnant in cases of incomplete abortion. This research
is done by quasi experimental method with one group pretest – posttest design. The
population of the study is all women who were diagnosed with incomplete abortion in
less than 12 weeks of gestation in Cipto Mangunkusumo National general Hospital and
affiliations hospital from June 2018 to June 2019. Women who met the study criteria,
was treated with oral misoprostol 600 mcg single dose and then undergo conception
evacuation evaluation and side effects evaluation. Effectiveness evaluation was seen
after 7 days of single dose 600 mcg of misoprostol by measuring <15 mm endometrial
thickness on transvaginal ultrasound. The effectiveness of using single dose oral
misoprostol 600 mcg in the study participants was 93.55%, which were 29 out of a total
of 31 participants. The side effects experienced after being given misoprostol were
bleeding with less than the same amount as menstruation (71.0% and 9.0%), diarrhea
(6.5%), and shivering (67.7%), and not found side effects of vomiting. Based on data
analysis using paired T test before and 24 hours after administration of misoprostol,
there was a significant difference between endometrial thickness (p value <0.001).
Misoprostol 600 mcg per oral dose is effective for the evacuation of retained conception
tissue of incomplete abortion at less than 12 weeks gestation, so that it can be an
alternative non-operative method of evacuating retained conception tissue in
incomplete abortion cases other than the operative method. Side effects found were
bleeding, diarrhea, and chills. Side effects of vomiting were not found in this study.
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Introduction
Abortion is a situation where
conception tissues are expelled out of
the womb before it is viable, which is
less than 500 grams or less than 20
weeks of gestational age (Cunningham et
al., 2014). It is known that about 30%-
40% of pregnancy results in an abortion,
whether known or unknown. In the
whole world, there were 40-70 cases of
abortion per 1000 productive females.
The frequency of abortion increases by
12% in females less than 20 years of age,
and increases up to 50% in females more
than 40 years of age (Seifert and Altman,
2015). The classification of abortion is
the basis of its treatment, where in
incomplete abortion, its treatment
consists of stabilizing hemodynamic
status and evacuation of retained
conception tissue. This evacuation can
be done by expectative management,
pharmacologic, of non-pharmacologic.
Misoprostol is well known by several
researches as a safe and effective agent
for evacuating retained conception
tissue (Cunningham et al., 2014).
According to International Federation of
Gynecology and Obstetrics (FIGO) and
WHO in 2017, the effective dose for
incomplete abortion is 600 mcg orally
(FIGO, 2017). Several researchers,
Paritakul and Phupong (2010), Diop and
colleagues (2009), Nguyen and
colleagues (2004), Weeks and colleagues
(2005), and Shwakerela and colleagues
(2007), Dao and colleagues (2007), and
Bique and colleagues (2007) reports that
using oral 600 mcg misoprostol for the
evacuation of retained conception tissue
of incomplete abortion is relatively an
effective method.
This research is aimed to know
the effectiveness of oral 600 mcg single
dose misoprostol in evacuating
incomplete abortion conception tissue in
gestations less than 12 weeks of age.
This research will also take note of any
side effects of misoprostol and whether
there is a difference of the endometrial
thickness before and 24 hours after the
administration of misoprostol.
Materials and Methods
This research was carried out
after obtaining the Faculty of Medicine-
Universitas Indonesia ethics committee's
approval (Number:
1248/UN2.F1/ETIK/2018) and research
permission from Koja District Hospital
and Karawang District Hospital. This
research was done by quasi
experimental method with one group
pretest – posttest design. The population
of the study was all females who were
diagnosed with incomplete abortion in
less than 12 weeks of gestation in Cipto
Mangunkusumo National Central
Hospital and its networks (Koja District
Hospital and Karawang District Hospital)
from June 2018 to June 2019.
The inclusion criterias of this
research were all females that present
with failure of pregnancy and diagnosed
with incomplete abortion less than 12
weeks of gestational age. The exclusion
criterias were the presence of molar or
ectopic pregnancy, the presence of
hemostasis imbalance, the presence of
cardiovascular or other vascular disease,
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the presence of intrauterine infection,
indwelling intrauterine device, allergies
to misoprostol or any other
prostaglandin analog, and participants
that were hemodynamically unstable.
Participants were selected
consecutively and were given
information about their participation in
the study that consists of information
about the purpose of this study,
incomplete abortion, misoprostol, and
side effects that may appear. Data were
collected primarily on participant’s
characteristics, hemodynamic status,
and endometrial thickness from
transvaginal ultrasound in the beginning.
Misoprostol 600 mcg were given orally.
Participants were observed for 24 hours
in the patient ward, and underwent
transvaginal ultrasound before being
discharged. Participants were scheduled
for control in 7 days after the
administration of misoprostol to the
gynecology clinic, where participants
once again were evaluated by
transvaginal ultrasound to measure the
endometrial thickness.
This study’s validity may be
questioned for it does not meet the
minimum sample count, but it satisfies
the theory that an experimental
research must meet at least 30 samples.
This lack of sample is possible because
the lack of incomplete abortion cases
that meets this research’s criteria, and
there are some patients who did not give
their consent.
Results and Discussion
There were 31 participants in
this study that were admitted for
incomplete abortion that satisfied the
inclusion and exclusion criteria. The
participant’s characteristics by age group,
formal education, occupation, parity,
and gestational age can be seen on Table
1.
This research found that the
frequency of incomplete abortion is at
its peak in the age above 30 years. This
finding is consistent with the research
done by Xiaobin and colleagues in 2018,
that mentions that age above 30 years
old has the highest risk to abortion
(Xiaobin et al., 2018). While research by
Putri (2018) found the samples were
dominated by age of 20-35 years old.
Spontaneous abortion is found in lower
education levels (high school and lower),
which are consistent with the findings by
Zheng and colleagues in 2017. This study
also finds that the frequency of
spontaneous abortions are lower in
working females, which is also consistent
with this research’s findings, which
collected data from 84,531 women in
China (Zheng et al., 2017). Xiaobin and
colleagues (2018) and Pitriani (2013)
found in their study that incomplete
abortions rise in risk in lower parities,
which are consistent with the findings of
this study, where nullipara and low
multipara has the highest rates of
incomplete abortion (29.0% and 58.1%).
There is no data found regarding the
distribution if gestational age in
incomplete abortions occurring in less
than 12 weeks of gestational age.
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Table 1. Participant’s characteristics distribution (n=31)
Characteristics Category Frequency Percentage (%)
Age Group < 20 years 2 6.5
20-30 years 13 41.9
> 30 years 16 51.6
Formal Education Lower education levels (high
school and lower)
26 83.8
Academy and higher 5 16.1
Occupation Working women 13 41.9
Non working women 18 58.1
Parity Nullipara (Gravida 1) 9 29.0
Low multipara
(Gravida 2-4)
18 58.1
Grande multipara
(>Gravida5)
4 12.9
Gestational Age < 8 weeks 10 32.3
8-12 weeks 21 67.7
Table 2. Effectivity of oral 600 mcg single dose misoprostol (n=31)
Category Frequency Percentage (%)
Successful (≤ 15 mm) 29 93.55
Failed (> 15 mm) 2 6.45
Table 3. Effectivity of oral 600 mcg single dose misoprostol based on gestational age
(n=31)
Evacuation
Successful Failed
Gestational Age
< 8 weeks 8 (80.0%) 2 (20.0%)
8-12 weeks 21 (100.0%) 0 (0.0%)
This research finds that the
effectiveness of oral 600 mcg single dose
misoprostol for the evacuation of
incomplete abortion retained products
of conception is 93.55% (Table 2), for it
succeeded in evacuating 29 out of 31
participants successfully. This finding is
consistent with the researches of
Paritakul and Phupong, even though
they found lower success rate of 87.5%.
They found a lower success rate maybe
because they evaluated the success rate
in 2x24 hours, whereas this research
done in 7 days (Paritakul and Phupong,
2010). Several other researches by
Nguyen and colleagues (2005), Weeks
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and colleagues (2005), Shwekerela and
colleagues (2007), Dao and colleagues
(2007), and Bique and colleagues (2007)
found similar success rate that ranges
through 91.0% and 99%.
Table 3 shows the success rate
after adjustments based on gestational
age. It was found that there are 2
participants that failed the misoprostol
treatment, which belong to the
gestational age group of less than 8
weeks. It is inconsistent with the findings
of Zikopoulos and colleagues (2002) that
the lower the gestational age, the higher
the success rate is. The reason why these
participants encounter failure in this
treatment is unknown and unable to be
explained, considering the small number
of study participants.
Table 4. Side effects distribution (n=31)
Side Effects Category Frequency Percentage (%)
Bleeding Less than menstruation 22 71.0
Equal to menstruation 9 29.0
More than menstruation 0 0
Vomiting No 31 100.0
Yes 0 0
Diarrhea No 29 93.5
Yes 2 6.5
Shivering No 21 67.7
Yes 10 32.3
The side effects of the
administration of oral 600 mcg single
dose of misoprostol that were evaluated
in this research consists of bleeding,
vomiting, diarrhea, and shivering (Table
4). Montesinos and colleagues (2011)
found that the side effect of bleeding
equal to and less than menstruation is
found in 22.6% and 50.0%, which is
consistent with the findings in our
research. Coyaji and colleagues (2007)
found that there is no side effect of
vomiting found in the administration of
oral 600 mcg single dose misoprostol,
just like this research. Montesinos and
colleagues (2011) also found that the
side effects of diarrhea were found in
4.7%, similar to the one found in this
research (6.5%). The side effect of
shivering was found in 32.3% of the
participants, similar to the findings of
the study done by Lumbiganon and
colleagues (1999).
The difference of endometrial
thickness before and 24 hours after the
administration of misoprostol can be
seen in Table 5. There is a significant
difference between the endometrial
thickness before and 24 hours after
misoprostol administration, based on
the statistical analysis. This finding is
better explained by the guideline from
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ACOG in 2018, where it was said that the
expulsion of retained products of
conception can be done by 24 hours
(Lumbiganon et al., 1999). After
adjustments of gestational age, there is a
significant difference between the
endometrial thickness before and 24
hours after misoprostol administration in
the 8-12 weeks of gestational age group.
But this study found no difference
between the endometrial thickness
before and 24 hours after misoprostol
administration in the less than 8 weeks
of gestational age group. This finding is
inconsistent to the theory that the lesser
the gestational age is, the better the
efficacy of misoprostol in expelling the
conception products, as it was said by
Zikopoulos and colleagues (2002) and
Lumbiganon et al. (1999). This
inconsistency in unable to be explained
considering the small number of study
participants.
Table 5. Difference in endometrial thickness before and 24 hours after the
administration of misoprostol
Endometrial
Thickness
Before Misoprostol
Administration (mm)
Endometrial
Thickness
After Misoprostol
Administration
(mm)
Difference
(mm)
P Value
Misoprostol 600 mcg 19.50 ± 10.16 11.19 ± 6.35 8.31 ± 8.95 < 0.001
Gestational
Age
< 8 weeks 18.51 ± 12.31 12.03 ± 8.77 6.48 ± 4.78 0.192
8-12
weeks
19.98 ± 9.28 10.79 ± 5.03 6.48 ± 4.78 < 0.001
Conclusion
Misoprostol 600 mcg per oral
dose is effective for the evacuation of
retained conception tissue of incomplete
abortion at less than 12 weeks gestation,
so that it can be an alternative non-
operative method of evacuating retained
conception tissue in incomplete abortion
cases other than the operative method.
Side effects found were bleeding,
diarrhea, and chills. Side effects of
vomiting were not found in this study.
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